byl719 and Lymphangioma

Lymphatic malformations (LMs) often pose treatment challenges due to a large size or a critical location that could lead to disfigurement, and there are no standardized treatment approaches for either refractory or unresectable cases.. We examined the genomic landscape of a patient cohort of LMs (. These LMs had low mutational burden with hotspot. Our findings establish that LM patients with conventional or kaposiform histology have distinct, yet targetable, driver mutations.. R.P. and W.A. are supported by awards from the Levy-Longenbaugh Fund. S.G. is supported by awards from the Hugs for Brady Foundation. This work has been funded in part by the NCI Cancer Center Support Grants (CCSG; P30) to the University of Arizona Cancer Center (CA023074), the University of New Mexico Comprehensive Cancer Center (CA118100), and the Rutgers Cancer Institute of New Jersey (CA072720). B.K.M. was supported by National Science Foundation via Graduate Research Fellowship DGE-1143953.. NCT03941782.

Topics: Antineoplastic Agents; Class I Phosphatidylinositol 3-Kinases; Class Ia Phosphatidylinositol 3-Kinase; Endothelial Cells; Genomics; GTP Phosphohydrolases; High-Throughput Nucleotide Sequencing; Humans; Immunohistochemistry; Lymphangioma; Lymphatic Abnormalities; Membrane Proteins; Mutation; Sequence Analysis, DNA; Thiazoles